Transient Myeloproliferative Disorder (Down Syndrome)
What is Transient Myeloproliferative Disorder (Down Syndrome)?
Transient myeloproliferative disorder, or TMD, is a condition that affects about 10% of newborns with Down syndrome. It happens when abnormal white blood cells called blasts build up in the blood and organs. These cells look like cancer cells but behave differently.
Most babies with TMD get better on their own within the first three months of life. The abnormal cells disappear without treatment in about 80% of cases. However, some babies develop serious complications, and about 20% to 30% later develop acute myeloid leukemia, a type of blood cancer, usually before age 4.
Early detection through blood testing helps doctors monitor babies at risk. Regular follow-up ensures that parents and care teams catch any progression early. Understanding TMD helps families know what to watch for and when to seek care.
Symptoms
- High white blood cell count detected on newborn blood tests
- Blast cells visible in blood samples
- Enlarged liver or spleen
- Jaundice, a yellowing of the skin and eyes
- Fluid buildup in tissues, causing swelling
- Skin nodules or blue-gray spots
- Breathing problems from fluid in the lungs
- Low platelet count leading to bleeding or bruising
Many babies with TMD have no symptoms at all. The condition is often found during routine blood tests after birth. Some babies have severe symptoms that need immediate treatment.
Concerned about Transient Myeloproliferative Disorder (Down Syndrome)? Check your levels.
Screen for 1,200+ health conditions
Causes and risk factors
TMD occurs because of genetic changes that affect blood cell development in babies with Down syndrome. The condition develops when babies have both trisomy 21, the extra chromosome that causes Down syndrome, and mutations in a gene called GATA1. These mutations happen randomly during early development.
The GATA1 gene helps control how blood cells grow and mature. When it mutates in babies who already have Down syndrome, blood stem cells make too many blast cells. These immature cells flood the bloodstream. Risk factors include being born with Down syndrome, especially with certain genetic variations. No lifestyle or environmental factors during pregnancy cause TMD.
How it's diagnosed
Doctors diagnose TMD through blood tests that measure white blood cell count and identify abnormal blast cells. A complete blood count, or CBC, shows elevated WBC levels. A blood smear lets lab technicians view the cells under a microscope to spot blasts. Genetic testing can confirm GATA1 mutations.
All newborns with Down syndrome should have blood testing within the first week of life to screen for TMD. Rite Aid offers testing through Quest Diagnostics at over 2,000 locations nationwide. Regular WBC monitoring helps track whether the condition is resolving or progressing. Additional tests may include liver function tests and bone marrow examination in some cases.
Treatment options
- Watchful waiting with regular blood tests for babies with mild TMD
- Supportive care including fluids, oxygen, and blood transfusions as needed
- Low-dose chemotherapy with cytarabine for babies with severe symptoms
- Treatment of complications like liver problems or fluid buildup
- Long-term monitoring with blood tests every 3 months until age 4
- Early intervention if acute myeloid leukemia develops
Concerned about Transient Myeloproliferative Disorder (Down Syndrome)? Get tested at Rite Aid.
- Simple blood draw at your nearest lab
- Results in days, not weeks
- Share results with your doctor
Frequently asked questions
TMD is a blood condition affecting some newborns with Down syndrome. Abnormal white blood cells called blasts build up in the blood and organs. Most cases resolve on their own within three months, but some babies need treatment or develop leukemia later.
About 10% of babies with Down syndrome develop TMD. Many more may have silent cases with few blast cells that go undetected. All newborns with Down syndrome should be tested because early detection matters for monitoring and care.
Many babies show no symptoms at all. When symptoms appear, they may include jaundice, an enlarged liver or spleen, swelling, or skin spots. High white blood cell counts on routine newborn tests often provide the first clue.
Yes, about 20% to 30% of babies with TMD develop acute myeloid leukemia before age 4. This is why ongoing blood test monitoring is so important. Regular WBC checks help doctors catch progression early when treatment works best.
Doctors use blood tests to diagnose TMD. A complete blood count measures white blood cell levels. Lab technicians examine blood smears under a microscope to identify blast cells. Genetic testing can confirm GATA1 mutations that drive the condition.
Most babies with mild TMD need only careful monitoring with regular blood tests. Babies with severe symptoms may need supportive care or low-dose chemotherapy. Treatment decisions depend on blast cell counts, organ involvement, and how sick the baby appears.
Babies diagnosed with TMD need frequent blood tests during the first few months to track resolution. After TMD clears, children should have blood tests every 3 months until age 4. This monitoring helps catch early signs of leukemia development.
TMD happens when babies have both Down syndrome and mutations in the GATA1 gene. The GATA1 mutation disrupts normal blood cell development, causing too many blast cells to form. These genetic changes occur randomly and are not caused by anything parents did.
No, TMD cannot be prevented because it results from random genetic mutations during development. However, early detection through newborn blood testing allows for proper monitoring. Catching TMD early helps doctors provide the right care at the right time.
Most babies with TMD recover fully within three months without treatment. About 70% to 80% never have problems again. The remaining children need ongoing monitoring and may develop leukemia, which is treatable when caught early through regular blood tests.